Publications (10) AINTZANE GARCIA BEA publications

filter_list

2021

  1. Di-aryl guanidinium derivatives: Towards improved α2-Adrenergic affinity and antagonist activity

    European Journal of Medicinal Chemistry, Vol. 209

  2. Opposite alterations of 5­HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile

    Translational Psychiatry, Vol. 11, Núm. 1

2019

  1. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gαi1-proteins

    European Neuropsychopharmacology, Vol. 29, Núm. 12, pp. 1453-1463

2017

  1. A group II metabotropic glutamate receptor 3 (mGlu3, GRM3) isoform implicated in schizophrenia interacts with canonical mGlu3 and reduces ligand binding

    Journal of Psychopharmacology, Vol. 31, Núm. 12, pp. 1519-1526

  2. Antipsychotic-induced Hdac2 transcription via NF-ΰ B leads to synaptic and cognitive side effects

    Nature Neuroscience, Vol. 20, Núm. 9, pp. 1247-1259

2016

  1. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia

    Science Signaling, Vol. 9, Núm. 410

  2. Metabotropic glutamate receptor 3 (mGlu3; mGluR3; GRM3) in schizophrenia: Antibody characterisation and a semi-quantitative western blot study

    Schizophrenia Research, Vol. 177, Núm. 1-3, pp. 18-27

  3. Novel targets for drug treatment in psychiatry

    The Medical Basis of Psychiatry: Fourth Edition (Springer New York), pp. 601-654

  4. Substituted conformationally restricted guanidine derivatives: Probing the α2-adrenoceptors’ binding pocket

    European Journal of Medicinal Chemistry, Vol. 123, pp. 48-57

2013

  1. Repressive epigenetic changes at the mglu2 promoter in frontal cortex of 5-HT2A knockout mice

    Molecular Pharmacology, Vol. 83, Núm. 6, pp. 1166-1175